Side-effects from imatinib treatment of advanced GIST–associated with a better outcome

Abstract

Background: Imatinib is considered to be the first-line therapy for patients with unresectable and/or metastatic gastrointestinal stromal cell

Successful treatment of bleeding large duodenal gastrointestinal stromal tumour in a patient under dual antiplatelet therapy after recent drug-eluting coronary stent implantation

“…While good response in neoadjuvant imatinib therapy is expected,10 severe adverse effects such as perforation or agranulocytosis with sepsis after imatinib therapy is reported 11. Tumour perforation can worsen prognosis probably due to peritoneal dissemination 12.…”

Improving adherence to oral anticancer therapy

“…2,4,6 Citrus fruit (grapefruit in particular) and pomegranate have been reported to interact with many oral targeted agents in oncology. 9 A study of 8,769 women with breast cancer who took hormonal therapy showed that overall adherence rates declined to 49% by year 4.5, consistent with a 7% to 10% increase in discontinuation or nonadherence for every year of daily oral therapy received. 9 A study of 8,769 women with breast cancer who took hormonal therapy showed that overall adherence rates declined to 49% by year 4.5, consistent with a 7% to 10% increase in discontinuation or nonadherence for every year of daily oral therapy received.…”

“…7,8 Problems with adherence When patients with cancer are treated with parenteral anticancer drugs, they report to the clinic where HCPs can consistently monitor their responses over the course of treatment. 1,[9][10][11] Nonetheless, despite the demonstrated benefits of oral anticancer agents and the recognized importance of treatment adherence on recurrence-free survival and overall survival, low adherence with oral therapies remains common. 4 Because oral therapies are considered easier to administer, you might expect adherence and persistence rates to be as good as, if not better than, those associated with parenteral therapies.…”

“…9,17,18,21 Interruption of treatment has been shown to result in rapid disease progression in both settings. GISTs represent the most common type of mesenchymal tumor of the GI tract.…”

Cancer therapeutics and research: novel developments

“…Hence, quality was assured in this process. Accepted manuscripts cover several areas such as research on a large variety of topics (apoptosis, cell cycle modulation, surgery, radiation, cachexia, tyrosine kinases, prevention, biomarkers) [2,3,4], clinical studies (covering many cancers, mostly focusing on single-institutional studies, although large databases also were used) [5], novel methodologies (metronomic therapy, but also radiation and surgical approaches) [5,6,7,8,9], and case reports (Figure 1). The latter was somewhat surprising and had special attention of the editors, since a case report should really describe novel aspects of a certain disease.…”